WAKLERT – for alertness and concentration | Buy in Ukraine with delivery

What is WAKLERT?

WAKLERT is a medicinal product belonging to the pharmacological group of psychostimulants and agents that enhance mental performance. The main active substance of the drug is armodafinil, which is the R-enantiomer of modafinil and is characterized by a longer and more stable action compared to its predecessor. The drug is available in the form of tablets for oral administration, which ensures convenience of administration and accurate dosing. WAKLERT is manufactured by the pharmaceutical company Sun Pharmaceutical Industries Ltd, one of the world's leading manufacturers of generic medicines with an impeccable reputation for product quality control.

The mechanism of action of WAKLERT consists in selective action on certain areas of the brain, in particular the hypothalamus, which is responsible for regulating sleep and wakefulness cycles. The drug increases dopamine levels in the synaptic cleft by blocking its reuptake, which leads to a pronounced wakefulness-promoting effect without a significant effect on the peripheral nervous system. Unlike classic amphetamine-type psychostimulants, WAKLERT does not cause severe euphoria, tremor, or a sharp increase in blood pressure, making its use safer in clinical practice. The therapeutic effect develops gradually within 1–2 hours after administration and lasts up to 12–15 hours, allowing the drug to be used once a day.

WAKLERT is widely used in neurological and psychiatric practice to correct conditions associated with pathological daytime sleepiness. The drug is not intended for self-medication and is available by prescription, as it requires careful diagnosis and determination of an individual therapeutic regimen. It is important to understand that WAKLERT does not replace full sleep, but only temporarily masks feelings of fatigue, so its use must be accompanied by sleep hygiene and lifestyle modification. The drug has undergone numerous clinical trials that confirmed its efficacy and relatively favorable safety profile when following the recommended dosages.

What is WAKLERT prescribed for?

The main indications for WAKLERT are conditions accompanied by excessive daytime sleepiness and sleep-wake cycle disorders. Primarily, the drug is prescribed to patients diagnosed with narcolepsy — a chronic neurological disorder in which a person experiences uncontrollable sleep attacks during the day, regardless of the quality of nighttime rest. WAKLERT helps such patients maintain sufficient alertness, reduces the frequency of sudden sleep episodes, and improves overall quality of life. The drug's efficacy in narcolepsy has been confirmed by multicenter, placebo-controlled trials showing a significant reduction in sleepiness scores on the Epworth scale.

The second important indication is obstructive sleep apnea syndrome, in which patients suffer from recurrent breathing pauses during sleep, leading to fragmentation of nighttime rest and pronounced daytime fatigue. WAKLERT is used as an adjunct in combination with the main treatment method — CPAP therapy, which provides continuous positive airway pressure. The drug helps compensate for residual sleepiness when device therapy does not completely eliminate symptoms. This approach allows patients to maintain performance and avoid dangerous situations associated with falling asleep at the wheel or while performing critical work.

WAKLERT is also prescribed for shift work sleep disorder, when professional activity requires nighttime activity or constant changes of time zones. The drug helps adapt the body to an unconventional schedule, reduces feelings of disorientation, and increases concentration during periods when the biological clock signals the need for sleep. In some clinical cases, a doctor may recommend WAKLERT for patients with severe asthenia or chronic fatigue, but such use is off-label and requires special caution. The decision to prescribe the drug is made exclusively by a doctor after a comprehensive examination and exclusion of other causes of sleepiness, such as anemia, hypothyroidism, or depressive disorders.

Composition and active ingredients of WAKLERT

Each WAKLERT tablet contains the active substance armodafinil in dosages of 50 mg, 150 mg, or 250 mg, which allows for flexible selection of a therapeutic regimen depending on individual patient needs. Armodafinil is the purified R-isomer of modafinil, providing a more predictable pharmacokinetics and a longer half-life of approximately 15 hours. Due to this property, the drug can be taken once a day, usually in the morning, without the need for repeated dosing during the day. Armodafinil has high oral bioavailability, which is not significantly affected by food intake, although high-fat food may slightly delay the rate of absorption.

WAKLERT tablets also contain excipients that ensure the stability of the drug, proper technological properties of the tablet mass, and optimal release of the active substance in the gastrointestinal tract. These include microcrystalline cellulose, croscarmellose sodium, povidone, lactose monohydrate, and magnesium stearate. Patients with rare hereditary lactose intolerance should consider the presence of this component and inform their doctor before starting therapy. Excipients do not have independent pharmacological activity, but play an important role in ensuring dosage accuracy and long shelf life of the drug.

The mechanism of action of armodafinil is realized through its effect on the dopaminergic system of the brain, specifically by inhibiting the dopamine transporter, which leads to an increase in dopamine concentration in the synaptic space. Additionally, the drug modulates the activity of histaminergic, noradrenergic, and orexinergic neurons, which form a complex neurotransmitter network responsible for maintaining wakefulness. Unlike traditional stimulants, WAKLERT does not cause generalized activation of the sympathetic nervous system, explaining the lower incidence of cardiovascular side effects. The drug also does not directly affect the structure of nighttime sleep when used with a proper dosing regimen, which is a significant advantage over other agents in this group.

Dosage of WAKLERT

The recommended starting dose of WAKLERT for adult patients is 150 mg once daily, taken in the morning with or without food. For patients with narcolepsy and obstructive sleep apnea syndrome, this dose is standard therapeutic and provides a stable wakefulness-promoting effect throughout the day. In cases of insufficient clinical response, the doctor may consider increasing the dose to the maximum of 250 mg per day; however, such a decision is made only after evaluating drug tolerability and ruling out adverse reactions. Exceeding the maximum daily dose does not lead to an increased therapeutic effect, but significantly increases the risk of adverse events.

For patients with shift work sleep disorder, the recommended dose of WAKLERT is 150 mg, taken approximately one hour before the start of the work shift. This regimen allows maximum plasma concentration of the drug to be achieved during the period when peak mental and physical performance is required. Elderly patients may require dose adjustment due to a physiological decline in liver and kidney function, which affects the metabolic rate of armodafinil. The doctor may recommend an initial dose of 50 mg with subsequent titration under monitoring of clinical response and tolerability.

The duration of WAKLERT treatment course is determined individually depending on the underlying disease and symptom dynamics. In narcolepsy and obstructive sleep apnea syndrome, therapy is usually long-term, sometimes lifelong, with periodic breaks to assess the need for continued treatment. In shift work sleep disorder, the drug can be used situationally, only on days when nighttime activity is required. Abrupt discontinuation of WAKLERT is usually not accompanied by severe withdrawal syndrome; however, temporary return of sleepiness symptoms is possible, so therapy adjustment should be conducted gradually under medical supervision.

How to take WAKLERT correctly?

WAKLERT is taken orally with a sufficient amount of water, preferably at the same time every day to maintain a stable plasma concentration of the drug. The tablet should be swallowed whole without chewing or crushing, as breaking tablet integrity may affect the release rate of the active substance. The drug can be taken on an empty stomach or after meals; however, it should be noted that eating a very fatty meal may delay the onset of the therapeutic effect by 1–2 hours. For patients working night shifts, optimal administration is 60 minutes before starting work, which ensures maximum concentration of armodafinil during the period of highest workload.

In case of a missed dose of WAKLERT, it should be taken as soon as possible if more than 8 hours remain until the next scheduled dose. If the missed dose is discovered later, skip the forgotten dose and return to your regular schedule without doubling the next dose to compensate. Doubling the dose significantly increases the risk of side effects such as headache, anxiety, tachycardia, and sleep disturbances. It is also important to avoid taking WAKLERT in the afternoon or evening, as the long half-life of the drug can cause insomnia and disruption of the circadian rhythm.

During WAKLERT therapy, it is recommended to abstain from alcohol, as ethanol can enhance the side effects of the drug and mask its therapeutic action. Patients should maintain a regular sleep schedule even if subjective feelings of fatigue have decreased, as the drug does not replace the body's physiological need for recovery. Women of childbearing potential taking hormonal contraceptives should be aware that WAKLERT can reduce their effectiveness due to liver enzyme induction; therefore, additional barrier methods of protection against unwanted pregnancy should be used. Before starting therapy, consultation with a doctor is mandatory to exclude contraindications and assess individual risks.

Side effects of WAKLERT

The most common side effects of WAKLERT, observed in more than 5% of patients, are headache, nausea, decreased appetite, and insomnia. Headache usually occurs at the beginning of therapy and tends to decrease during the first week of administration, although in some cases it may require symptomatic treatment with analgesics. Nausea and decreased appetite are associated with the drug's effect on hunger regulation centers in the hypothalamus, so patients are recommended to eat small meals throughout the day. Insomnia occurs mainly when the dosing schedule is violated, particularly when taking the drug later than recommended, and usually resolves after adjusting the dosing schedule.

Less common adverse reactions include anxiety, irritability, dizziness, dry mouth, and increased blood pressure. Patients prone to anxiety disorders may experience worsening of symptoms and require special monitoring during the first weeks of therapy. The increase in blood pressure is usually moderate and does not require drug discontinuation; however, regular blood pressure monitoring is recommended for patients with arterial hypertension. Rare but serious side effects are allergic reactions, including angioedema, Stevens-Johnson syndrome, and erythema multiforme, which require immediate discontinuation of the drug and medical attention.

In rare cases, WAKLERT may cause psychiatric disorders such as hallucinations, manic states, or suicidal ideation, especially in patients with a history of psychiatric conditions. The appearance of any unusual changes in mood, behavior, or thinking is a reason for immediate consultation with a doctor. It should be remembered that individual body response to the drug may vary, so if any adverse symptoms occur, even those not listed in the instructions, you must inform your doctor. Regular medical follow-up allows for timely detection of potential complications and adjustment of the therapeutic strategy.

Contraindications of WAKLERT

An absolute contraindication to the use of WAKLERT is hypersensitivity to armodafinil, modafinil, or any of the excipients of the drug. Patients with a history of allergic reactions to drugs in this group should avoid WAKLERT due to the risk of developing severe skin reactions. The drug is not recommended for patients with severe anxiety, psychomotor agitation, or psychotic disorders, as central nervous system stimulation may exacerbate these conditions. Another contraindication is the presence of severe cardiovascular diseases, including uncontrolled arterial hypertension, recent myocardial infarction, or unstable angina.

WAKLERT is not prescribed to children and adolescents under 18 years of age, as the safety and efficacy of the drug in this age group have not been established in adequate clinical trials. Use of the drug during pregnancy is not recommended due to potential risk to the fetus, as armodafinil crosses the placental barrier. Women of childbearing potential should rule out pregnancy before starting therapy and use reliable methods of contraception throughout treatment and for two months after its completion. The period of breastfeeding is also a contraindication, as it is unknown whether armodafinil passes into breast milk, but the potential risk to the infant outweighs the possible benefit to the mother.

WAKLERT should be prescribed with caution to patients with impaired liver function, as drug metabolism occurs mainly in the liver with the participation of cytochrome P450. In moderate hepatic impairment, a dose reduction by half may be required, and in severe impairment, the drug is contraindicated. Patients with renal impairment also require cautious use and possible dose adjustment, although renal clearance is not the main elimination pathway for the drug. For individuals with a history of epilepsy or seizure disorders, WAKLERT may be prescribed only after a careful assessment of the benefit-risk ratio, as central nervous system stimulants may lower the seizure threshold.

Interactions of WAKLERT with other drugs and alcohol

WAKLERT can affect the activity of liver enzymes, in particular inducing cytochrome CYP3A4 and inhibiting CYP2C19, which is relevant during concomitant use with other medicinal products. The drug can reduce the effectiveness of hormonal contraceptives, including oral, transdermal, and implantable forms; therefore, women are advised to use barrier methods of protection. Concomitant administration of WAKLERT with anticoagulants (warfarin), antiepileptic drugs, and antidepressants requires monitoring of their blood concentrations and appropriate dose adjustment. Patients taking cyclosporine should consider that armodafinil may reduce its blood levels, posing a risk of transplant rejection.

Consumption of alcohol during WAKLERT therapy is not recommended, as ethanol can enhance central nervous system side effects of the drug, such as dizziness, impaired coordination, and decreased concentration. In addition, alcohol can mask the therapeutic effect of the drug, leading to an unwarranted dose increase and an increased risk of toxic reactions. Patients should also consider that WAKLERT may affect the ability to drive vehicles and operate complex machinery, especially at the start of therapy or when changing the dose. Although the drug usually improves alertness, some individuals may experience dizziness or visual disturbances, requiring caution when performing potentially hazardous activities.

Where to buy WAKLERT in Ukraine

WAKLERT is available in Ukraine through a network of licensed pharmacies authorized to sell prescription medicines. The drug is dispensed strictly by prescription, which guarantees its proper use and minimizes the risks of self-medication. Patients can purchase WAKLERT both in physical pharmacy establishments and through online platforms working with certified suppliers of pharmaceutical products. Before purchasing, it is important to check the seller's license and the drug's compliance with the original packaging to avoid buying counterfeit products.

Storage conditions for WAKLERT require keeping the drug in a dry place, protected from light, at a temperature not exceeding 25 degrees Celsius. The drug should be kept out of reach of children and not used after the expiration date stated on the package. Many online pharmacies offer convenient delivery of the drug throughout Ukraine, which is especially important for patients with chronic conditions requiring continuous therapy. However, even with the availability of remote ordering, the decision to start or continue WAKLERT treatment must be made solely by a qualified doctor based on a clinical assessment of the patient's condition.